AbbVie Financial Statements (ABBV)
|
|
|
|
Report date
|
|
|
18.02.2022 |
17.02.2023 |
20.02.2024 |
14.02.2025 |
20.02.2026 |
|
20.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
56 197 |
58 054 |
54 318 |
56 334 |
61 160 |
|
61 160 |
|
Operating Income, bln rub |
|
|
17 924 |
18 117 |
12 757 |
9 137 |
20 091 |
|
16 340 |
|
EBITDA, bln rub |
? |
|
23 933 |
24 174 |
17 172 |
14 910 |
17 629 |
|
17 629 |
|
Net profit, bln rub |
? |
|
11 542 |
11 836 |
4 863 |
4 278 |
4 226 |
|
4 226 |
|
|
OCF, bln rub |
? |
|
22 777 |
24 943 |
22 839 |
18 806 |
19 030 |
|
19 030 |
|
CAPEX, bln rub |
? |
|
787.0 |
695.0 |
777.0 |
974.0 |
1 214 |
|
1 337 |
|
FCF, bln rub |
? |
|
21 990 |
24 248 |
22 062 |
17 832 |
17 816 |
|
18 701 |
|
Dividend payout, bln rub
|
|
|
9 261 |
10 043 |
10 539 |
11 025 |
11 657 |
|
11 657 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
80.2% |
84.9% |
216.7% |
257.7% |
275.8% |
|
275.8% |
|
|
OPEX, bln rub |
|
|
20 827 |
22 523 |
21 146 |
30 293 |
22 865 |
|
26 616 |
|
Cost of production, bln rub |
|
|
17 446 |
17 414 |
20 415 |
16 904 |
18 204 |
|
18 204 |
|
R&D, bln rub |
|
|
8 046 |
6 510 |
7 675 |
12 791 |
9 096 |
|
9 096 |
|
Interest expenses, bln rub |
|
|
2 423 |
2 230 |
2 224 |
2 808 |
2 893 |
|
2 893 |
|
|
Assets, bln rub |
|
|
146 529 |
138 805 |
134 711 |
135 161 |
133 960 |
|
133 960 |
|
Net Assets, bln rub |
? |
|
15 408 |
17 254 |
10 360 |
3 325 |
-3 270 |
|
-3 270 |
|
Debt, bln rub |
|
|
77 575 |
64 191 |
60 120 |
67 841 |
69 068 |
|
68 874 |
|
Cash, bln rub |
|
|
9 830 |
9 229 |
12 816 |
5 555 |
5 257 |
|
5 257 |
|
Net debt, bln rub |
|
|
67 745 |
54 962 |
47 304 |
62 286 |
63 811 |
|
63 617 |
|
|
Ordinary share price, rub |
|
|
135.4 |
161.6 |
155.0 |
177.7 |
228.5 |
|
205.0 |
|
Number of ordinary shares, mln |
|
|
1 770 |
1 771 |
1 768 |
1 769 |
1 780 |
|
1 780 |
|
|
Market cap, bln rub |
|
|
239 658 |
286 211 |
273 987 |
314 351 |
406 802 |
|
364 945 |
|
EV, bln rub |
? |
|
307 403 |
341 173 |
321 291 |
376 637 |
470 613 |
|
428 562 |
|
Book value, bln rub |
|
|
-92 922 |
-82 341 |
-77 543 |
-91 699 |
-91 551 |
|
-91 551 |
|
|
EPS, rub |
? |
|
6.52 |
6.68 |
2.75 |
2.42 |
2.37 |
|
2.37 |
|
FCF/share, rub |
|
|
12.4 |
13.7 |
12.5 |
10.1 |
10.0 |
|
10.5 |
|
BV/share, rub |
|
|
-52.5 |
-46.5 |
-43.9 |
-51.8 |
-51.4 |
|
-51.4 |
|
|
EBITDA margin, % |
? |
|
42.6% |
41.6% |
31.6% |
26.5% |
28.8% |
|
28.8% |
|
Net margin, % |
? |
|
20.5% |
20.4% |
8.95% |
7.59% |
6.91% |
|
6.91% |
|
FCF yield, % |
? |
|
9.18% |
8.47% |
8.05% |
5.67% |
4.38% |
|
5.12% |
|
ROE, % |
? |
|
74.9% |
68.6% |
46.9% |
128.7% |
-129.2% |
|
-129.2% |
|
ROA, % |
? |
|
7.88% |
8.53% |
3.61% |
3.17% |
3.15% |
|
3.15% |
|
|
P/E |
? |
|
20.8 |
24.2 |
56.3 |
73.5 |
96.3 |
|
86.4 |
|
P/FCF |
|
|
10.9 |
11.8 |
12.4 |
17.6 |
22.8 |
|
19.5 |
|
P/S |
? |
|
4.26 |
4.93 |
5.04 |
5.58 |
6.65 |
|
5.97 |
|
P/BV |
? |
|
-2.58 |
-3.48 |
-3.53 |
-3.43 |
-4.44 |
|
-3.99 |
|
EV/EBITDA |
? |
|
12.8 |
14.1 |
18.7 |
25.3 |
26.7 |
|
24.3 |
|
Debt/EBITDA |
|
|
2.83 |
2.27 |
2.75 |
4.18 |
3.62 |
|
3.61 |
|
|
R&D/CAPEX, % |
|
|
1 022% |
936.7% |
987.8% |
1 313% |
749.3% |
|
680.3% |
|
|
CAPEX/Revenue, % |
|
|
1.40% |
1.20% |
1.43% |
1.73% |
1.98% |
|
2.19% |
|
| AbbVie shareholders |
